1. Hong Kong Stocks

  2. •

    Financial Services

  3. •

    Financial - Credit Services
Zhong Ji Longevity Science Group Limited

Zhong Ji Longevity Science Group Limited

0767.HK
Zhong Ji Longevity Science Group LimitedHK flagHong Kong Stock Exchange
0.50
HKD
+0.01
- -
318.33MMarket Cap
Zhong Ji Longevity Science Group Limited
0767.HK
(Hong Kong Stock Exchange)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
38.99
31.57
1.25
0.24
0.23
0.37
1.62
0.71
0.47
0.38
0.05
0.04
0.06
0.04
0.2
0.27
Revenue per Share
677.43
-79.31
2.24
0.6
-0.09
-0.53
0.94
0.21
-5.68
-2.13
-0.01
- -
- -
- -
-0.04
-0.03
Basic EPS, GAAP
-518.41
-218.59
7.9
-0.79
-0.46
-0.32
0.13
-0.28
0.48
-0.05
-0.14
-0.03
0.01
0.01
-0.07
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-368.93
41.54
2.27
1.92
-0.23
-0.77
0.27
0.44
-2.62
-4.78
-1.63
-1.63
-1.6
-1.57
-0.92
-1.47
Book Value per Share
816.82
242.59
13.82
5.49
4.57
7.01
5.54
5.16
4.05
2.5
0.31
0.32
0.28
0.28
0.48
0.72
Tangible Book Value per Share
- -
2
28
125
278
278
342
387
387
387
1,478
1,478
1,517
1,547
836
593
Basic Weighted Avg Shares
4
53
35
30
65
102
555
273
180
146
80
61
90
65
166
162
Sales/Revenue/Turnover
-105.49
53.56
-21.1
-29.06
60.89
31.39
70.6
50.53
45.62
63.9
-18.36
16.18
13.5
-37.96
-5.68
-15.15
Operating Margin (%)
49
- -
1
1
1
1
4
1
3
4
2
4
4
7
7
6
Depreciation Expense
76
-134
62
76
-26
-148
322
82
-2,199
-826
-11
6
-1
2
-35
-17
Net Income, GAAP
2.8
- -
- -
- -
- -
- -
21.14
32.04
- -
- -
- -
10.92
92.48
46.83
- -
- -
Effective Tax Rate (%)
1,737.56
-251.23
179.39
254.6
-39.91
-144.68
57.96
30.1
-1,221.39
-566.13
-14.35
9.91
-1.01
3.56
-20.9
-10.36
Profit Margin (%)
87
365
181
420
474
807
1,176
1,245
1,039
299
156
232
246
250
372
399
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
4
3
3
LT Debt
92
410
690
992
1,512
4,135
4,081
4,180
1,567
967
455
471
421
430
400
425
Total Equity
-1.51
- -
- -
-1.01
- -
- -
7.46
2.26
- -
- -
- -
1.89
0.2
-2.87
- -
- -
Return on Invested Capital (%)
39.02
- -
- -
40.55
- -
- -
-637.82
50.8
- -
- -
- -
-0.28
0.1
-0.13
- -
- -
Return on Capital (%)
- -
- -
93.5
49.83
- -
- -
- -
62.7
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.83%
-1.13%
6.21%
Free Cash Flow
-57.55%
-143.27%
-62.55%
Net Income, GAAP
-560.21%
-455.32%
-51.76%
Sales/Revenue/Turnover
44.15%
29.72%
-2.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
65
2024
- -
- -
- -
- -
166
2025
- -
- -
- -
- -
162

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Stellar Capital Services Limited (STELLAR.BO)
CCUR Holdings, Inc. (CCUR)
Butn Limited (BTN.AX)
Sunbelt Rentals Holdings Inc (SUNB)
Hao Wen Holdings Limited (8019.HK)
Elevate Credit, Inc. (ELVT)
Business
Zhong Ji Longevity Science Group Limited (0767.HK), an investment holding company incorporated in Bermuda in 1994 and headquartered in Kowloon Bay, Hong Kong, principally engages in longevity science and money lending businesses in Hong Kong and Mainland China. The company operates through five main segments: Longevity Science, encompassing research, medical testing, biological products such as NMN and vitamin C sustained-release tablets, management services, and membership divisions; Money Lending and Financial Advisory, providing credits and consulting; Securities and Other Investments, holding equity and financial assets; Property Investment, for rental income and capital appreciation; and health consulting with medical product trading. It offers diagnostic consultations, cancer prevention and immunity supplements, longevity wine distribution, and healthcare testing services targeting high-net-worth individuals and health-focused markets. Recent developments include the appointment of Mr. Yan Li as executive chairman and CEO effective October 17, 2025, following resignations of prior executives; a collaboration agreement signed September 13, 2025, with Hainan Boao Super Hospital to establish an International Precision Oncology Medical Center; a memorandum of understanding with China International Osteoarticular Medical Group for acquiring Asian Integrated Cell Laboratory to advance cell therapies for cancer prevention, anti-aging, and knee health; an announced acquisition of 25% stake in Asian Integrated Cell Laboratory for HK$300 million as of December 1, 2025; and a July 29, 2025, memorandum of cooperation with Haoshiduo to enhance diagnostics and medical services.